Physician profile
Joyce L Horn
NPI 1558340224
$830.75
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $34.61 · 2021: $32.49 · 2022: $375 · 2023: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.26 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $92.78 | 2022-2023 | |
| Pfizer INC. | $67.68 | 2019-2023 | |
| Therapeuticsmd, INC. | $60.75 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.37 | 2019-2020 | |
| Gynesonics, INC. | $56.70 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Coopersurgical, INC. | $50.17 | 2022-2023 | Paragard T 380a |
| Shield Therapeutics INC | $41.67 | 2023 | Accrufer |
| Hologic Sales and Service, LLC | $29.49 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $27.75 | 2019-2020 | |
| Scynexis, INC. | $21.16 | 2022 | |
| Sumitomo Pharma America, INC. | $20.87 | 2023 | Myfembree |
| Astellas Pharma US INC | $17.32 | 2023 | Myrbetriq |
| Exeltis, USA INC. | $15.43 | 2022 | |
| Avion Pharmaceuticals | $11.35 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.